Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Non-Deal Roadshow (August 2023)
22 slides from Nova Eye Medical's roadshow presentation, Aug 3, 2023
Slide 1: Addressing the Leading Causes of Blindness
Addressing the Leading Causes of Blindness August 2023
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Business Snapshot
BUSINESS SNAPSHOT Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Commercial
Slide 4: Company Overview
COMPANY OVERVIEW Capital Structure Share Price Chart ASX Code EYE 6,000,000 $0.35 Share Price (at 28 July 2023) $0.26 Shares on Issue 190 M 5,000,000 $0.30 Unlisted Options 3.35 M Market Capitalisation $49.4 M 4,000,000 $0.25 Cash Capital raise 2 March 2023 3,000,000 ~$7.5 M $0.20 Top 20 Shareholder
Slide 5: Our Glaucoma Opportunity
OUR GLAUCOMA OPPORTUNITY • With a proprietary product portfolio and an established glaucoma salesforce, Nova Eye Unique intellectual property drives product Medical is well positioned to execute its portfolio. glaucoma opportunity. • The new iTrack™ Advance canaloplasty device, cleared by the USA Fo
Slide 6: Glaucoma, Disease Overview
GLAUCOMA, DISEASE OVERVIEW • Glaucoma is the leading cause of blindness in the developed world • Progressive, irreversible eye disease that causes vision loss due to optic nerve damage. • Elevated intraocular pressure (IOP) is the most significant risk factor for the development of glaucoma. 2 • The
Slide 7: Glaucoma, Treatment Overview
GLAUCOMA, TREATMENT OVERVIEW • Traditional treatment paradigm consisted of Patient adherence to glaucoma long-term chronic medication use. medications is poor • Patients and surgeons are moving away from 10-25% of newly prescribed patients don’t refill second medications in favour of minimally invas
Slide 8: Microcatheter designed for canaloplasty
• Microcatheter designed for canaloplasty • Strong body of clinical evidence but technically challenging– requires use of forceps, cutting instruments • Used predominantly by glaucoma surgeons nova-eye.com | 8
Slide 9: iTrack Advance
9 iTrack™ Advance • Our iTrack™ Advance MIGS device is redefining the treatment of glaucoma in its early stages. • Enhanced version of our original iTrack™ microcatheter, which was first brought to market in 2008 and has been used in more than 120,000 procedures globally. • Offers a stent-free, tiss
Slide 10: iTrack Advance
10 iTrack™ Advance NEW IMAGE REQUIRED 3 2 1
Slide 11: iTrack Advance
11 iTrack™ Advance
Slide 12: Glaucoma, Market Overview
GLAUCOMA, MARKET OVERVIEW • The glaucoma consumable surgical devices market is the fastest growing US$667m segment of the ophthalmic market. CAGR 15% • The aging global population drives 144.2 Glaucoma Surgical Device market size and growth rate prevalence, representing a significant million per ann
Slide 13: Glaucoma Market – Accessing Fast Growing Segment
GLAUCOMA MARKET – ACCESSING FAST GROWING SEGMENT Glaucoma interventions1 (2022 to 2027) Surgical glaucoma interventions are forecast to grow at Glaucoma surgical 14.70 14.7% per annum globally over the next 5 years. The device 20.0% % Compound 15.0% 10% fastest growing form of glaucoma surgery inter
Slide 14: Canal Surgery Segment Market Growth
CANAL SURGERY SEGMENT MARKET GROWTH Global Canal Surgery Procedures 2017 to 2027 800 ('000's) Forecast growth 20% 700 Number of procedures ('000's) 600 500 400 300 200 100 0 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 • Canal Surgery Segment Procedures growth rate of 20% forecast between
Slide 15: Glaucoma, by Geography
GLAUCOMA, BY GEOGRAPHY China Improved access to healthcare driving surgeon demand Well networked distribution US$37 partner with direct sales force million growing at 31%1 Germany USA Nova Eye Medical Nova Eye, Inc GmbH New Zealand Molteno Ophthalmic Ltd World’s largest market for German sales team
Slide 16: In the USA, iTrack is regularly used by approx. 200 specialist glaucoma surgeons
In the USA, iTrack™ is regularly used by approx. 200 1,3001 200 specialist glaucoma surgeons. The new existing surgeon customers estimated iTrack Advance will appeal to the additional ™ glaucoma surgeon market 1,100 glaucoma surgeons and the additional 10,000 comprehensive and cataract surgeons. “iT
Slide 17: USA Sales Update
USA SALES UPDATE Following the USA launch of iTrack™ Advance at the ASCRS meeting in May 2023, 1 total USA sales in the three (3) months to 31 July 2023 were approx. US$2.2 million, up 32% on the pcp 2 Solid sales growth in the USA is expected to continue, with a targeted program of new customer acc
Slide 18: Our Glaucoma Outlook
OUR GLAUCOMA OUTLOOK Glaucoma consumable surgical devices represent the fastest growing market in 1 ophthalmology. 2 Best-in-class iTrack™ Advance device approved for sale in the USA, the world’s largest market. 3 Established, scalable glaucoma salesforce and commercial infrastructure in USA. 4 Well
Slide 19: AlphaRET for Retinal Disease
ALPHARET FOR RETINAL DISEASE • Age-related macular degeneration (AMD) is the leading cause of blindness in industrialised countries in people over the age of 50 2RT® is a proprietary, world-first years. nanosecond laser therapy to treat • Late-stage Wet AMD market is currently the only market served
Slide 20: Overview of AMD Market
Overview of AMD Market Intermediate stage disease – AlphaRET Late stage macular degeneration (Treats underlying causes of AMD.) Wet Dry Intermediate Intermediate AMD (CNV) AMD (GA) AMD AMD Choroidal Geographic Atrophy Neovascularization 54 million 14 million people 55 million 15 million people world
Slide 21: 2RT Development Milestones and Plan
2RT® DEVELOPMENT MILESTONES AND PLAN Our strategy for 2RT® is to collect additional clinical data at sites in Europe, Australia, Canada and ultimately the USA to gain FDA clearance for the treatment of intermediate AMD funded by partners. ✓ PRE-CLINCAL WORK Continuing work on Investigational Device
Slide 22: Contact
22 Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8362 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com